|
1
|
Deorah S, Lynch CF, Sibenaller ZA and
Ryken TC: Trends in brain cancer incidence and survival in the
United States: surveillance, epidemiology, and end results program,
1973 to 2001. Neurosurg Focus. 20:E12006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group: Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hardie DG: AMP-activated/SNF1 protein
kinases: conserved guardians of cellular energy. Nat Rev Mol Cell
Biol. 8:774–785. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kato K1, Ogura T, Kishimoto A, Minegishi
Y, Nakajima N, Miyazaki M and Esumi H: Critical roles of
AMP-activated protein kinase in constitutive tolerance of cancer
cells to nutrient deprivation and tumor formation. Oncogene.
21:6082–6090. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lizcano JM, Göransson O, Toth R, Deak M,
Morrice NA, Boudeau J, Hawley SA, Udd L, Mäkelä TP, Hardie DG and
Alessi DR: LKB1 is a master kinase that activates 13 kinases of the
AMPK subfamily, including MARK/PAR-1. EMBO J. 23:833–843. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Manning G, Whyte DB, Martinez R, Hunter T
and Sudarsanam S: The protein kinase complement of the human
genome. Science. 298:1912–1934. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martin MJ, Carling D and Marais R: Taking
the stress out of melanoma. Cancer Cell. 15:163–164. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ashrafian H: Cancer's sweet tooth: the
Janus effect of glucose metabolism in tumorigenesis. Lancet.
367:618–621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Legembre P, Schickel R, Barnhart BC and
Peter ME: Identification of SNF1/AMP kinase-related kinase as an
NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced
motility and invasiveness. J Biol Chem. 279:46742–46747. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lefebvre DL, Bai Y, Shahmolky N, Sharma M,
Poon R, Drucker DJ and Rosen CF: Identification and
characterization of a novel sucrose-non-fermenting protein
kinase/AMP-activated protein kinase-related protein kinase, SNARK.
Biochem J. 355:297–305. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zagórska A, Deak M, Campbell DG, Banerjee
S, Hirano M, Aizawa S, Prescott AR and Alessi DR: New roles for the
LKB1-NUAK pathway in controlling myosin phosphatase complexes and
cell adhesion. Sci Signal. 3:ra252010.PubMed/NCBI
|
|
13
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baek D, Villén J, Shin C, Camargo FD, Gygi
SP and Bartel DP: The impact of microRNAs on protein output.
Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Shi ZM, Jiang CF, Liu X, Chen QD,
Qian X, Li DM, Ge X, Wang XF, Liu LZ, et al: MiR-143 acts as a
tumor suppressor by targeting N-RAS and enhances
temozolomide-induced apoptosis in glioma. Oncotarget. 5:5416–5427.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heck S, Rom J, Thewes V, Becker N, Blume
B, Sinn HP, Deuschle U, Sohn C, Schneeweiss A and Lichter P:
Estrogen-related receptor alpha expression and function is
associated with the transcriptional coregulator AIB1 in breast
carcinoma. Cancer Res. 69:5186–5193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS,
Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S and Sarkar FH:
Metformin inhibits cell proliferation, migration and invasion by
attenuating CSC function mediated by deregulating miRNAs in
pancreatic cancer cells. Cancer Prev Res (Phila). 5:355–364. 2012.
View Article : Google Scholar
|
|
18
|
Yu F, Li J, Chen H, Fu J, Ray S, Huang S,
Zheng H and Ai W: Kruppel-like factor 4 (KLF4) is required for
maintenance of breast cancer stem cells and for cell migration and
invasion. Oncogene. 30:2161–2172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang SN, Singh C, Nall D, Meeker D,
Shankar S and Srivastava RK: The dietary bioflavonoid quercetin
synergizes with epigallocathechin gallate (EGCG) to inhibit
prostate cancer stem cell characteristics, invasion, migration and
epithelial-mesenchymal transition. J Mol Signal. 5:142010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Suvà ML, Riggi N, Janiszewska M,
Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino
D, Cironi L, et al: EZH2 is essential for glioblastoma cancer stem
cell maintenance. Cancer Res. 69:9211–9218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeppernick F, Ahmadi R, Campos B, Dictus
C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B and
Herold-Mende CC: Stem cell marker CD133 affects clinical outcome in
glioma patients. Clin Cancer Res. 14:123–129. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Godlewski J, Nowicki MO, Bronisz A,
Williams S, Otsuki A, Nuovo G, Raychaudhury A, Newton HB, Chiocca
EA and Lawler S: Targeting of the Bmi-1 oncogene/stem cell renewal
factor by microRNA-128 inhibits glioma proliferation and
self-renewal. Cancer Res. 68:9125–9130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakai E, Park K, Yawata T, Chihara T,
Kumazawa A, Nakabayashi H and Shimizu K: Enhanced MDR1 expression
and chemoresistance of cancer stem cells derived from glioblastoma.
Cancer Invest. 27:901–908. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Son MJ, Woolard K, Nam DH, Lee J and Fine
HA: SSEA-1 is an enrichment marker for tumor-initiating cells in
human glioblastoma. Cell Stem Cell. 4:440–452. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sherry MM, Reeves A, Wu JK and Cochran BH:
STAT3 is required for proliferation and maintenance of multipotency
in glioblastoma stem cells. Stem Cells. 27:2383–2392. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bao S, Wu Q, Li Z, Sathornsumetee S, Wang
H, McLendon RE, Hjelmeland AB and Rich JN: Targeting cancer stem
cells through L1CAM suppresses glioma growth. Cancer Res.
68:6043–6048. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pasquinelli AE, Reinhart BJ, Slack F,
Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B,
Müller P, et al: Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature.
408:86–89. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reinhart BJ, Slack FJ, Basson M,
Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR and Ruvkun G:
The 21-nucleotide let-7 RNA regulates developmental timing in
Caenorhabditis elegans. Nature. 403:901–906. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Saito Y, Liang G, Egger G, Friedman JM,
Chuang JC, Coetzee GA and Jones PA: Specific activation of
microRNA-127 with down-regulation of the proto-oncogene BCL6 by
chromatin-modifying drugs in human cancer cells. Cancer Cell.
9:435–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Varambally S, Cao Q, Mani RS, Shankar S,
Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Corson TW, Huang A, Tsao MS and Gallie BL:
KIF14 is a candidate oncogene in the 1q minimal region of genomic
gain in multiple cancers. Oncogene. 24:4741–4753. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Namiki T1, Tanemura A, Valencia JC, Coelho
SG, Passeron T, Kawaguchi M, Vieira WD, Ishikawa M, Nishijima W,
Izumo T, et al: AMP kinase-related kinase NUAK2 affects tumor
growth, migration, and clinical outcome of human melanoma. Proc
Natl Acad Sci USA. 108:6597–6602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bjerkvig R, Tysnes BB, Aboody KS, Najbauer
J and Terzis AJ: Opinion: the origin of the cancer stem cell:
current controversies and new insights. Nat Rev Cancer. 5:899–904.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Donnenberg VS and Donnenberg AD: Multiple
drug resistance in cancer revisited: the cancer stem cell
hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
|
